^a The worldwide patient number is largely comprised of patients treated with DUPIXENT from 11 countries (Brazil, Canada, China, France, Germany, Italy, Japan, the Netherlands, Spain, UK, and US) and the rest of the world comprising ≈12% of this worldwide patient number. This number is composed of the following US approved indications: AD, AFRS, asthma, BP, COPD, CRSwNP, CSU, PN, and EoE. Data through March 2026.